Clinical evaluation of the T-SPOT.TB test for detection of tuberculosis infection in northeastern Guangdong Province, China.
T-SPOT.TB
TB
Tuberculosis
diagnosis
receiver operator characteristic analysis
sensitivity
Journal
The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
2
6
2020
pubmed:
2
6
2020
medline:
9
3
2021
Statut:
ppublish
Résumé
We evaluated clinical performance of the T-SPOT.TB test for detecting tuberculosis (TB) infection in Meizhou, China. We enrolled 2,868 patients who underwent T-SPOT.TB, smear, and TB-DNA at the same time. The tests' sensitivity and specificity were evaluated and compared in different groups, and in pulmonary TB (PTB) and extrapulmonary TB (EPTB) subgroups. Receiver operator characteristic (ROC) curve analysis was used to evaluate T-SPOT.TB's diagnostic value and determine its cutoff value. T-SPOT.TB, TB-DNA, and sputum smear sensitivity was 61.44%, 37.12%, and 14.02%; and specificity was 76.49%, 99.20% and 99.60%, respectively. The T-SPOT.TB positive rate was higher in the PTB and EPTB subgroups than in patients with other pulmonary diseases (61.38% and 61.76% vs. 23.34%). The T-SPOT.TB test had better diagnostic accuracy and sensitivity when the positive cutoff value of marker ESAT-6 was 2.5 [area under ROC curve = 0.701, 95%CI 0.687-0.715] and marker CFP-10 was 6.5 [area under ROC curve = 0.669, 95%CI 0.655-0.683]. T-SPOT.TB sensitivity was higher than that of TB-DNA or sputum smear, but the specificity was lower. T-SPOT.TB had moderate sensitivity and specificity for diagnosing TB. T-SPOT.TB's new positive cutoff value may be clinically valuable according to ROC analysis.
Identifiants
pubmed: 32475200
doi: 10.1177/0300060520923534
pmc: PMC7263121
doi:
Substances chimiques
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
300060520923534Références
Lancet Infect Dis. 2015 Mar;15(3):310-9
pubmed: 25681063
J Infect. 2012 Jul;65(1):39-48
pubmed: 22484244
Mayo Clin Proc. 2011 Apr;86(4):348-61
pubmed: 21454737
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Int J Infect Dis. 2015 Nov;40:108-12
pubmed: 26358858
Eur J Intern Med. 2012 Jun;23(4):363-7
pubmed: 22560387
J Clin Pathol. 2000 Oct;53(10):727-32
pubmed: 11064664
Clin J Am Soc Nephrol. 2007 Jan;2(1):68-73
pubmed: 17699389
Lancet Infect Dis. 2006 Sep;6(9):570-81
pubmed: 16931408
Respirology. 2010 Feb;15(2):220-40
pubmed: 20199641
Methods Mol Biol. 2015;1325:197-205
pubmed: 26450390
Clin Microbiol Infect. 2016 Jul;22(7):613-9
pubmed: 27139592
Microbiol Spectr. 2017 Jan;5(1):
pubmed: 28185620
Mol Microbiol. 2004 Jan;51(2):359-70
pubmed: 14756778
BMJ. 2016 Jan 13;352:h6747
pubmed: 26762607
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
J Microbiol Biotechnol. 2014 Jul;24(7):1004-7
pubmed: 24786527
Sci Rep. 2017 Aug 10;7(1):7764
pubmed: 28798488
Indian J Pediatr. 2000 Feb;67(2 Suppl):S1-2
pubmed: 11129901
J Rheumatol. 2009 Mar;36(3):546-51
pubmed: 19228655
Sci Rep. 2017 Jul 18;7(1):5743
pubmed: 28720801
Infect Immun. 2000 Jun;68(6):3314-21
pubmed: 10816479
Clin Vaccine Immunol. 2015 May;22(5):510-5
pubmed: 25739918
Expert Rev Anti Infect Ther. 2007 Jun;5(3):327-31
pubmed: 17547496
Tuberculosis (Edinb). 2009 Dec;89 Suppl 1:S5-9
pubmed: 20006306
Lancet. 2014 Jun 14;383(9934):2057-2064
pubmed: 24650955
New Microbiol. 2007 Jul;30(3):286-90
pubmed: 17802911
J Biol Chem. 2002 Jun 14;277(24):21598-603
pubmed: 11940590
Paediatr Drugs. 2005;7(4):219-34
pubmed: 16117559
Glob Health Action. 2014 Jun 12;7:23620
pubmed: 24929074
Jpn J Infect Dis. 2010 Mar;63(2):99-102
pubmed: 20332570
Eur J Clin Microbiol Infect Dis. 2005 Aug;24(8):529-36
pubmed: 16133410